Agenus’ (AGEN) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Agenus (NASDAQ:AGEN) in a report released on Friday morning,Benzinga reports. HC Wainwright currently has a $7.00 price target on the biotechnology company’s stock.

A number of other equities analysts also recently commented on AGEN. B. Riley cut their target price on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. StockNews.com lowered Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $10.00.

Agenus Stock Performance

AGEN opened at $3.42 on Friday. Agenus has a 1 year low of $2.50 and a 1 year high of $19.69. The firm has a 50 day moving average price of $4.15 and a 200 day moving average price of $8.06. The company has a market cap of $80.23 million, a PE ratio of -0.30 and a beta of 1.39.

Hedge Funds Weigh In On Agenus

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 DIFC Ltd purchased a new stake in shares of Agenus during the second quarter worth about $51,000. EP Wealth Advisors LLC purchased a new stake in Agenus during the 3rd quarter worth approximately $55,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Agenus during the 2nd quarter worth approximately $106,000. HighTower Advisors LLC raised its position in shares of Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 7,530 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 9,422 shares during the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.